STAT+: Kura Oncology secures approval for leukemia drug, its first
The Food and Drug Administration on Thursday approved a drug made by Kura Oncology to treat patients with a certain type of genetically altered leukemia.
The medicine will be sold under the brand name Komzifti.
The FDA cleared the drug to treat patients with relapsed or refractory acute myeloid leukemia, or AML, caused by a mutation in a gene called NPM1. The mutation, which makes AML more difficult to treat, is a driver of approximately 30% of all AML cases.
Adam Feuerstein
Go to statnews